You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 25 No. 1, July 1971 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Parkinsonism-Dementia and Amyotrophic Lateral Sclerosis of Guam

Effect of Probenecid on Monoamine Catabolite Levels in Cerebrospinal Fluid

Thomas N. Chase, MD; James A. Schnur, MD; Jacob A. Brody, MD; Edna K. Gordon

Arch Neurol. 1971;25(1):9-13.


Abstract

Changes in cerebrospinal fluid (CSF) levels of homovanillic acid (HVA), a major catabolite of dopamine and of 5-hydroxyindoleacetic acid (5-HIAA), the principle product of serotonin degradation, were compared in Guamanian parkinsonism-dementia (PD) and amyotrophic lateral sclerosis (ALS) patients with Guamanian and North American control subjects during the administration of probenecid. The rise of both HVA and 5-HIAA was significantly less in PD patients than in control subjects. Values for both these monoamine catabolites in patients with ALS consistently fell between those of PD patients and controls. Since probenecid inhibits the efflux of HVA and 5-HIAA from CSF, these results suggest that a substantial reduction in the synthesis of both dopamine and serotonin may attend PD and ALS of Guam.



Author Affiliations

Bethesda, Md

From the Laboratory of Clinical Science (Dr. Chase and Mrs. Gordon), National Institute of Mental Health, and the Epidemiology Branch (Drs. Schnur and Brody), National Institute of Neurologic Diseases and Stroke, Bethesda, Md.


Footnotes

Accepted for publication Jan 7, 1971.

Reprint requests to Section on Experimental Therapeutics, National Institute of Mental Health, Bethesda, Md 20014 (Dr. Chase).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

CSF Monoamine Metabolites in Child and Adult Psychiatric Patients: A Developmental Perspective
Leckman et al.
Arch Gen Psychiatry 1980;37:677-681.
 

Inosiplex and Amyotrophic Lateral Sclerosis: Therapeutic Trial in Patients on Guam
Brody et al.
Arch Neurol 1974;30:322-323.
ABSTRACT  

Amyotrophic Lateral Sclerosis: A Study of Central Monoamine Metabolism and Therapeutic Trial of Levodopa
Mendell et al.
Arch Neurol 1971;25:320-325.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1971 American Medical Association. All Rights Reserved.